<DOC>
	<DOCNO>NCT00110071</DOCNO>
	<brief_summary>This phase I trial study side effect best dose fludarabine ( fludarabine phosphate ) give together iodine I 131 tositumomab treat old patient undergo autologous syngeneic stem cell transplant relapse refractory B-cell non-Hodgkin 's lymphoma ( NHL ) . Radiolabeled monoclonal antibody , iodine I 131 tositumomab , find cancer cell carry cancer-killing substance without harm normal cell . Drugs use chemotherapy , fludarabine , work different way stop growth cancer cell , either kill cell stop dividing . A peripheral stem cell transplant may able replace blood-forming cell destroy chemotherapy radiation therapy . Giving iodine I 131 tositumomab together fludarabine follow autologous stem cell transplant may effective treatment NHL</brief_summary>
	<brief_title>Iodine I 131 Tositumomab Fludarabine Phosphate Treating Older Patients Who Are Undergoing Autologous Syngeneic Stem Cell Transplant Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximally tolerate dose fludarabine combine 131I-anti-CD20 ( iodine I 131 tositumomab ) deliver = &lt; 27Gy critical normal organ follow autologous syngeneic transplantation patient &gt; = 60 year age relapse B-NHL . SECONDARY OBJECTIVES : I . To assess overall progression-free survival regimen patient . II . To evaluate response rate therapy . III . To evaluate toxicity tolerability therapy . IV . To evaluate feasibility deliver concurrent high-dose radioimmunotherapy ( RIT ) chemotherapy . OUTLINE : This dose-escalation study fludarabine phosphate use combination I 131 tositumomab stem cell transplant . Patients receive dosimetric dose iodine I 131 tositumomab intravenously ( IV ) 40-60 minute day -24 follow gamma camera image next 6 day . Patients receive therapeutic dose iodine I 131 tositumomab via central line 40-60 minute day -14 . Patients also receive fludarabine phosphate IV daily ( QD ) day -11 -9 OR day -11 -7 . Patients undergo autologous syngeneic peripheral blood stem cell transplantation day 0 . Patients circulate lymphoma cell peripheral smear receive tositumomab IV 1 hour OR rituximab IV 1 hour follow tositumomab IV 1 hour dosimetric iodine I 131 tositumomab infusion . After completion study treatment , patient follow 1 , 3 , 6 , 12 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis lymphoma express CD20 antigen generally must fail least one prior standard systemic therapy ; exception mantle cell lymphoma ( MCL ) patient , may enrol first complete remission ( CR ) accordance current transplant standard care patient Creatinine ( Cr ) &lt; 2.0 Bilirubin &lt; 1.5 mg/dL , exception patient think Gilbert 's syndrome , may total bilirubin 1.5 mg/dL All patient eligible therapeutic study must ( &gt; = 2x10^6 CD34/kg ) autologous hematopoietic stem cell harvest cryopreserved , number cell harvest syngeneic donor Patients must expect survival &gt; 60 day must free major infection DONOR : Syngeneic donor must confirm syngeneic ABO typing , human leukocyte antigen ( HLA ) typing , variable number tandem repeat ( VNTR ) analysis DONOR : Syngeneic donor must meet eligibility Standard Practice Guidelines/Standard Treatment Circulating antimouse antibody ( HAMA ) ( determine dosimetry therapy ) Systemic antilymphoma therapy give previous 30 day schedule therapy dose Inability understand give inform consent Prior radiation &gt; 20 Gy critical normal organ ( e.g. , lung , liver , spinal cord , &gt; 25 % red marrow ) Central nervous system lymphoma Other serious medical condition consider represent contraindication bone marrow transplant ( BMT ) ( e.g. , abnormally decreased cardiac ejection fraction , diffuse capacity ( DLCO ) &lt; 50 % predict , patient supplemental oxygen , acquire Immunodeficiency syndrome [ AIDS ] , etc . ) Pregnancy Prior bone marrow stem cell transplant South West Oncology Group ( SWOG ) performance status &gt; = 2 Unable perform selfcare radiation isolation Patients chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma/well differentiate lymphocytic lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>